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Case 1.
A 17 yr old female suffering from recurrent medulloblastoma was admitted for prolonged pancytopenia due to topotecan maintenance therapy. Throughout her medical history, this patient had received intensive therapy, including high dose chemotherapy and autologous peripheral blood stem cell transplantation, craniospinal irradiation, as well as CNS-directed therapy, namely intrathecal chemotherapy and radioimmunotherapy (Table 1) . Thirty minutes after receiving a cryopreserved autologous stem cell boost, the patient complained of bilateral loss of vision initially. Fifteen minutes later, she became unconscious (Glasgow coma scale 3/15). The patient was in cardiorespiratory stable condition. During transport to emergency CT, she developed one short episode of clonic seizure restricted to both arms, which responded promptly to dexamethasone. Her CT scan revealed no signs of ischemia or bleeding, her EEG displayed moderate dysrhythmia. Cerebrospinal fluid analysis revealed normal lactate, protein and glucose, and did not contain leucocytes or malignant cells. Likewise, serum LETTERS TO THE EDITOR 
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electrolytes, glucose, LDH were within normal ranges. The patient remained unconscious for approximately two hours. When she woke up, she was disoriented for an additional hour. Three hours after the incident, she had completely recovered, but showed retrograde amnesia for the complete episode. She was discharged the following day without any neurological symptoms. Following the stem cell boost, she recovered from neutropenia and thrombocytopenia after 14 days. Follow-up MRT one month later showed no specific findings. Case 2. A 7 month old male infant diagnosed with fibrosarcoma of his lower back who had responded well to preceding chemotherapy, but still had non-operable residual disease extending into his spinal canal was considered eligible for haploidentical stem cell transplant as consolidation therapy after extensive consultation and written parental consent. Following the standard conditioning regimen of Fludarabin, Thiotepa and Melphalan, he was transplanted with a cryopreserved CD3/CD19-depleted haploidentical stem cell graft from his father. Forty minutes following infusion, he suddenly lost consciousness. His cardiorespiratory condition was stable. Serum electrolytes, blood gases were within normal ranges. Emergency cranial ultrasound revealed no pathology, EEG was normal. In addition, he showed no clinical signs of seizure. One hour after the onset of symptoms, the infant gradually regained consciousness. Two hours after the onset, he had completely recovered.
DMSO is currently the only sufficiently validated reagent for cryopreservation of hematopoietic stem cells, standard practice in most centers is cryoconservation with 10% DMSO).
9 However, stem cell washing 10 before infusion or cryopreservation with DMSO mixed with hydroxyethyl starch 11 may represent alternative approaches. In children, few data on neurotoxicity following infusion of DMSO-PBSC are available. 8 The incidence in our series of consecutive stem cell infusions was found to be 2/131 (1.5 %). The only other report in children 8 thus far had implicated morphine co-medication as contributing factor which can be ruled out in our two patients. Furthermore, post-thaw viability of both products was within the expected range (78 and 74%, respectively) excluding the assumption that an inadequately high number of dead or apoptotic cells might have contributed to neurotoxicity. Other triggers such as disturbances of electrolytes, glucose or blood gases, intravascular activation of coagulation could be excluded in both patients. The time to onset was within the first sixty minutes after infusion, in accordance with the majority of reports in adults.
1,2,3,5
Toxicology analysis of DMSO in rodents indicates a dose-dependent increase in neurotoxicity. 12 The first patient who had received only a relatively small amount of DMSO (146 mg/kg), may have been more sensitive to the neurotoxic effects due to her brain tumor and to prior intensive CNS-directed therapy. The second patient, an infant without prior CNS history, developed symptoms at a dose level of 814 mg/kg, which is in the higher end of the applicable dose range). 2 Certainly, children with a body weight of 10kg and below are at risk for receiving higher dosage of DMSO. As a consequence of the observed toxicities, our institutional policy has changed to keep the maximum volume applied at 4 mL/kg cryopreserved stem cells containing 10% DMSO and to recommend to split doses on subsequent infusion days, if necessary.
